# Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy

> **NCT01451450** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Peanut Allergy

## Interventions

- **DRUG:** QGE031
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01451450
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01451450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01451450, "Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01451450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*